Biosimilar Product Development Meetings With FDA To Be Flexible Under User Fee Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency says pre-marketing application meetings will not be mandatory; program independence issue also appears resolved.
You may also be interested in...
Biosimilar User Fee Program Stresses FDA/Sponsor Meetings Early And Often
BsUFA agreement negotiated between the agency and industry provides five different types of meetings during the pre-IND and product development stage. FDA will issue a draft guidance on the different types of biosimilar meeting opportunities by 2014.
Biosimilar Players Will Be Manufacturers Large And Small, Analyst Predicts
The biosimilar manufacturing and development process has been optimized to ensure multiple companies can enter the market, Sanford C. Bernstein & Co. Senior Health Care Analyst Ronny Gal argues, but uncertainty will remain until FDA designs its approval system.
Biosimilar Players Will Be Manufacturers Large And Small, Analyst Predicts
The biosimilar manufacturing and development process has been optimized to ensure multiple companies can enter the market, Sanford C. Bernstein & Co. Senior Health Care Analyst Ronny Gal argues, but uncertainty will remain until FDA designs its approval system.